Core Insights - Plus Therapeutics has received approval for a new Category III CPT code from the American Medical Association to track the utilization of convection-enhanced delivery (CED) for REYOBIQ therapy in recurrent glioblastoma and pediatric brain cancer, marking a significant step towards market access and commercialization [1][2] Group 1: REYOBIQ Therapy - REYOBIQ (rhenium Re186 obisbemeda) is a novel injectable radiotherapy designed to deliver targeted high-dose radiation to CNS tumors, potentially improving patient outcomes compared to existing therapies [3] - The therapy is currently being evaluated in clinical trials for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer, with significant funding support from various institutions, including a $17.6 million grant from the Cancer Prevention & Research Institute of Texas [3] Group 2: Market Access and Utilization Tracking - The approved Category III CPT code, X566T, will facilitate the tracking of CED procedures for REYOBIQ, aiding in the evaluation of its clinical use and supporting future reimbursement and coverage decisions [2] - The new CPT code will be published on July 1, 2026, and will take effect for reporting on January 1, 2027, which is expected to enhance the adoption of REYOBIQ in clinical settings [2] Group 3: Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for challenging CNS cancers, aiming to improve clinical outcomes through innovative treatment approaches [4] - The company has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [4]

Core Insights - Plus Therapeutics is focused on scaling up the commercialization of CNSide and preparing for pivotal trials of REYOBIQ in 2026 [2][6] Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Houston, Texas, developing targeted radiotherapeutics for challenging CNS cancers [10] - The company aims to enhance clinical outcomes through a combination of image-guided local beta radiation and targeted drug delivery [10] Clinical Programs - REYOBIQ (rhenium Re186 obisbemeda) is a novel injectable radiotherapy designed for CNS tumors, with potential advantages over existing therapies [6] - The REYOBIQ clinical program includes trials for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer [6][8] - The ReSPECT-LM trial is expected to report data in Q3 2026, while the ReSPECT-GBM trial aims to complete enrollment and align with the FDA on pivotal trial design by Q4 2026 [7] Financial Updates - The company recently completed a $15 million offering to support its core business areas and extend its cash runway through 2027 [2] - Plus Therapeutics aims to cover 150 million US lives under various commercial payor agreements and achieve over 1,250 tests per year in commercial orders [7] CNSide Diagnostics - CNSide Diagnostics, a subsidiary of Plus Therapeutics, develops proprietary tests to identify tumor cells in the CNS, improving management for patients with leptomeningeal metastases [9]

Core Insights - Plus Therapeutics, Inc. is advancing novel treatments for leptomeningeal metastases (LM) with its products REYOBIQ™ and ReSPECT-LM, showcasing promising clinical trial results at upcoming conferences [1][2] Group 1: Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers [6] - The company is headquartered in Houston, Texas, and aims to enhance clinical outcomes through innovative therapies [6] Group 2: Product Information - REYOBIQ (rhenium Re186 obisbemeda) is an injectable radiotherapy designed for targeted high-dose radiation in CNS tumors, potentially improving patient outcomes compared to existing therapies [4] - REYOBIQ has received FDA Fast Track and Orphan Drug Designation, with ongoing enrollment in the ReSPECT-LM Dose Optimization Trial [2][4] Group 3: Clinical Trials and Results - The ReSPECT-LM Phase 1 trial demonstrated excellent tolerance of REYOBIQ at higher doses than current standards, indicating a broad therapeutic range [2] - Clinical benefit rate for REYOBIQ exceeded 75% across three relevant outcome measures, with no dose-limiting toxicities observed [6] Group 4: Market Need and Context - Leptomeningeal metastases occur in approximately 5% of metastatic cancer patients, with limited effective treatment options available, highlighting the urgent need for new therapies [3] - Median survival for patients with LM is typically between 2-6 months, underscoring the critical demand for innovative solutions [3]

Core Insights - Plus Therapeutics, Inc. has announced positive results from its RESPECT-LM Phase 1 clinical trial and has introduced the CNSide® CSF diagnostics platform with a national coverage agreement with UnitedHealthcare, covering over 51 million people in the U.S. [1][9] Corporate Overview - The company is focused on three main business verticals: diagnostics, therapeutics, and capital structure, with plans to expand its commercial team and footprint for CNSide [3] - Plus Therapeutics reported a cash and investments balance of $16.6 million as of September 30, 2025, a significant increase from $6.9 million on June 30, 2025, and $3.6 million on December 31, 2024 [7] - The company regained compliance with Nasdaq listing criteria, including market value and stockholder's equity thresholds [8] Clinical Trials and Product Development - Positive results from the ReSPECT-LM Phase 1 trial were presented, indicating that treatment of leptomeningeal metastases with REYOBIQ is feasible and shows promising efficacy [5] - The CNSide CSF assay platform demonstrated the ability to quantify leptomeningeal metastases over time and monitor changes in targetable mutations, potentially aiding in treatment initiation [9] Financial Performance - For Q3 2025, Plus Therapeutics reported a net loss of $4.4 million, or $0.04 per share, compared to a net loss of $2.9 million, or $0.37 per share, in Q3 2024 [15][21] - Total operating loss for Q3 2025 was $4.5 million, an increase from a loss of $3.8 million in the same quarter of 2024, primarily due to higher compensation and professional fees [15] Strategic Partnerships and Market Position - The company received an additional $1.9 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT) as part of a previously awarded non-dilutive grant for cancer-targeted radiotherapeutics [8] - CNSide Diagnostics, a subsidiary of Plus Therapeutics, has made its CSF assay platform commercially available in Texas, focusing on National Cancer Institute Designated Cancer Centers [9][12]

Core Insights - Plus Therapeutics, Inc. has received an advance payment of $1.6 million from the Cancer Prevention and Research Institute of Texas (CPRIT) as part of a $17.6 million grant for the development of targeted radiotherapeutics for leptomeningeal cancer [1][2] - The company expects to receive an additional $6 million in funding over the next 12 months, which will provide significant non-dilutive financing to support its clinical programs [2] - Plus Therapeutics is developing REYOBIQ™, a novel injectable radiotherapy aimed at treating CNS tumors, and is conducting clinical trials for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer [4][7] Funding and Financial Support - The funding from CPRIT, along with active grants from the NIH and DoD, reflects strong institutional support for Plus Therapeutics' clinical programs and enhances its capital position for long-term growth [2] - CPRIT is recognized as the second-largest public cancer research funder globally, with a mission to invest in cancer research and prevention initiatives in Texas [5] Clinical Development and Research - Leptomeningeal metastases (LM) occur in approximately 5% of patients with metastatic cancer, with limited effective treatment options available, highlighting the need for innovative therapies [3] - REYOBIQ is designed to deliver targeted high-dose radiation specifically to CNS tumors, potentially improving patient outcomes compared to existing therapies [4] - The CNSide diagnostic test is being developed to identify tumor cells that have metastasized to the central nervous system, which is crucial for managing patients with leptomeningeal metastases [6]

Core Insights - Plus Therapeutics is set to present the final results of its ReSPECT-LM clinical trial at the SNO/ASCO CNS Metastases Conference, highlighting the safety and efficacy of its treatment for leptomeningeal metastases [1][2] - The company will also host an educational symposium focusing on advancements in managing leptomeningeal metastases, featuring presentations from leading neuro-oncologists [3] Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Houston, Texas, specializing in targeted radiotherapeutics for central nervous system cancers [8] - The company is advancing a pipeline of product candidates, particularly in the areas of leptomeningeal metastases and recurrent glioblastoma, utilizing image-guided local beta radiation and targeted drug delivery [8] Product Information - REYOBIQ (rhenium Re186 obisbemeda) is a novel injectable radiotherapy developed by Plus Therapeutics, designed to deliver targeted high-dose radiation to CNS tumors [6] - REYOBIQ is currently being evaluated in clinical trials for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer, with significant funding support from various institutions [6] Industry Context - Leptomeningeal metastases are a severe complication of advanced cancer, occurring in approximately 5% of metastatic cancer patients, with limited effective treatment options available [5] - The median survival for patients with leptomeningeal metastases is typically between 2 to 6 months, underscoring the urgent need for novel therapies [5]

Core Insights - Plus Therapeutics, Inc. is focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers, with a particular emphasis on leptomeningeal metastases (LM) and recurrent glioblastoma (GBM) [5] - The company's subsidiary, CNSide Diagnostics, will present its CNSide Cerebrospinal Fluid (CSF) Assay Platform at the SNO/ASCO CNS Metastases Conference, showcasing its clinical utility in managing patients at risk for CNS metastases [1][2] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company headquartered in Houston, Texas, developing advanced platform technologies for CNS cancers [5] - CNSide Diagnostics specializes in proprietary laboratory-developed tests to identify tumor cells that have metastasized to the CNS, enhancing patient management for those with leptomeningeal metastases [3] Industry Context - Leptomeningeal metastases occur in approximately 5% of patients with metastatic cancer, with breast cancer, lung cancer, and melanoma being the most common sources [4] - Median survival for patients with LM is typically between 2 to 6 months, indicating a significant need for novel therapeutic options [4]

Core Insights - Plus Therapeutics is set to launch its CNSide CSF Assay Platform in the U.S. market in the second half of 2025, targeting a significant unmet need in CNS cancer diagnostics with a market opportunity exceeding $6 billion [1][2][4] Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers [14] - The company has invested over $300 million in the CNSide technology, which aims to address the clinical need for better diagnostic tools in CNS cancer [3] Product Details - The CNSide CSF Assay Platform is designed for patients suspected of having CNS cancer metastases, with the first test, CNSide CSF Tumor Cell Enumeration (TCE), expected to be commercialized soon [2][4] - The platform has demonstrated high sensitivity (92%) and specificity (95%) in diagnosing CNS metastases, influencing treatment decisions in 90% of cases [5] Market Opportunity - CNS metastases affect approximately 30% of adult cancer patients, and the current standard of care for diagnosis is outdated, leading to missed or delayed diagnoses [4] - The CNSide platform is positioned to provide superior clinical utility compared to the current standard of care, which has been validated through real-world use and peer-reviewed publications [5] Commercial Strategy - Plus Therapeutics has established a scalable testing laboratory in Houston, TX, and is executing a commercial market access strategy that includes state licensure and reimbursement codes [6][7] - The company anticipates launching the CNSide platform in Texas first, followed by expansion into additional states [6] Financial Outlook - The revenue contributions from the CNSide subsidiary are expected to become meaningful to Plus Therapeutics' operations in fiscal year 2026 [9]